Amicus Therapeutics Inc. minced no words on the failure of its phase III study of SD-101 in epidermolysis bullosa (EB), the object of a potential $847 million take-out of Scioderm Inc., but John Crowley, Amicus chairman and CEO, was equally quick to defend the merits of the acquisition on a conference call Wednesday.